Biomolecules (Sep 2022)

t<sup>6</sup>A and ms<sup>2</sup>t<sup>6</sup>A Modified Nucleosides in Serum and Urine as Strong Candidate Biomarkers of COVID-19 Infection and Severity

  • Yu Nagayoshi,
  • Kayo Nishiguchi,
  • Ryosuke Yamamura,
  • Takeshi Chujo,
  • Hiroyuki Oshiumi,
  • Hiroko Nagata,
  • Hitomi Kaneko,
  • Keiichi Yamamoto,
  • Hirotomo Nakata,
  • Korin Sakakida,
  • Akihiro Kunisawa,
  • Masataka Adachi,
  • Yutaka Kakizoe,
  • Takanori Mizobe,
  • Jun-ichi Kuratsu,
  • Shinya Shimada,
  • Yasushi Nakamori,
  • Masao Matsuoka,
  • Masashi Mukoyama,
  • Fan-Yan Wei,
  • Kazuhito Tomizawa

DOI
https://doi.org/10.3390/biom12091233
Journal volume & issue
Vol. 12, no. 9
p. 1233

Abstract

Read online

SARS-CoV-2 infection alters cellular RNA content. Cellular RNAs are chemically modified and eventually degraded, depositing modified nucleosides into extracellular fluids such as serum and urine. Here we searched for COVID-19-specific changes in modified nucleoside levels contained in serum and urine of 308 COVID-19 patients using liquid chromatography-mass spectrometry (LC-MS). We found that two modified nucleosides, N6-threonylcarbamoyladenosine (t6A) and 2-methylthio-N6-threonylcarbamoyladenosine (ms2t6A), were elevated in serum and urine of COVID-19 patients. Moreover, these levels were associated with symptom severity and decreased upon recovery from COVID-19. In addition, the elevation of similarly modified nucleosides was observed regardless of COVID-19 variants. These findings illuminate specific modified RNA nucleosides in the extracellular fluids as biomarkers for COVID-19 infection and severity.

Keywords